2 unchanged sentences
Exhibit Description
−Removed: Third Amended and Restated Bylaws of PDS Biotechnology Corporation (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K
−Removed: filed on March 15, 2022, and incorporated by reference herein).
−Removed: PDS Biotechnology Corporation Change of Control Severance Plan effective as of March 14, 2022 (filed as Exhibit 10.21 to the
−Removed: Company’s Annual Report on Form 10-K filed on March 31, 2022, and incorporated herein by reference).
−Removed: Amended and Restated Executive Employment Agreement by and between Frank K.
−Removed: Bedu-Addo and PDS Biotechnology Corporation, effective as
−Removed: of March 14, 2022 (filed as Exhibit 10.22 to the Company’s Annual Report on Form 10-K filed on March 31, 2022, and incorporated herein by reference).
−Removed: Executive Employment Agreement by and between Gregory Conn, Ph.D.
−Removed: and PDS Biotechnology Corporation, effective as of March 14, 2022
−Removed: (filed as Exhibit 10.23 to the Company’s Annual Report on Form 10-K filed on March 31, 2022, and incorporated herein by reference).
−Removed: Executive Employment Agreement by and between Matthew Hill and PDS Biotechnology Corporation, effective as of March 14, 2022 (filed
−Removed: as Exhibit 10.24 to the Company’s Annual Report on Form 10-K filed on March 31, 2022, and incorporated herein by reference).
−Removed: Executive Employment Agreement by and between Lauren V.
−Removed: and PDS Biotechnology Corporation, effective as of March 14, 2022
−Removed: (filed as Exhibit 10.25 to the Company’s Annual Report on Form 10-K filed on March 31, 2022, and incorporated herein by reference).
−Removed: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as
−Removed: adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as
−Removed: adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Executive Employment Agreement by and between Spencer Brown and PDS Biotechnology Corporation, effective as of June 1, 2022.
+Added: Amended and Restated Preclinical/Clinical Collaboration and License Agreement dated as of November 30, 2020 by and between PDS
+Added: Biotechnology Corporation and Farmacore Biotechnology.
+Added: First Amendment to Preclinical/Clinical Collaboration and License Agreement dated as of November 22, 2021 by and between PDS
+Added: Biotechnology Corporation and Farmacore Biotechnology.
+Added: PDS Biotechnology Corporation 2019 Inducement Plan, as amended (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K
+Added: filed on May 18, 2022 and incorporated herein by reference).
+Added: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934,
+Added: as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934,
+Added: as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer Pursuant to 18 U.S.C.
4 unchanged sentences
Sarbanes-Oxley Act of 2002 (furnished herewith).
−Removed: XBRL Instance Document
+Added: XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
XBRL Taxonomy Extension Schema Document
7 unchanged sentences
Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
−Removed: Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
+Added: Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
PDS Biotechnology Corporation
+Added: August 8, 2022
/s/ Frank Bedu-Addo
2 unchanged sentences
(Principal Executive Officer)
+Added: August 8, 2022
/s/ Matthew Hill
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.